Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2339 - Effect of apatinib combined with 5-fluorouracil (5-FU) on proliferation, apoptosis and invasiveness of gastric cancer cells


11 Sep 2017


Poster display session


Clinical Research;  Cancer Biology;  Gastric Cancer


Pengfei ZHAO


Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361


P. ZHAO1, J. Zhang2, X. Pang1, L. Zhao1, Q. Li1, B. Cao1

Author affiliations

  • 1 Department Of Oncology, Beijing Friendship Hospital, 100020 - Beijing/CN
  • 2 Department Of Food Science, Shandong Medicine Technician College, 271016 - Tai'an/CN


Abstract 2339


To investigate the effect of apatinib, a small-molecule tyrosine kinase inhibitor, combined with 5-FU on proliferation, apoptosis and invasiveness of human gastric cancer cells AGS, and provide experimental basis for the treatment of two drugs combination in gastric cancer in clinic.


The expression of vascular endothelial growth factor receptor 2 (VEGFR2) protein in human umbilical vein endothelial cells (HUVEC) and human gastric cancer cells were assessed by western blotting. 4-methyl-teerazolium (MTT) assay and flow cytometry were used to assess the cytotoxicity and apoptosis effects of the cells in response to control, single apatinib, single 5-FU, and apatinib combined 5-FU groups. Western blotting was used to evaluate the expression of p-Akt, proliferating cell nuclear antigen (PCNA), Caspase-3 and the invasiveness differences of the four groups were detected by wound healing assay and matrix metalloprotein-2 (MMP-2), E-cadherin gene amplification were measured by RT-PCR.


AGS had the expression of VEGFR2. Compared with single drug groups, apatinib combined with 5-FU could significantly suppress the growth, proliferation and induce apoptosis of human gastric cancer cells in time and dose-dependent manners (P


Our study points that apatinib combined 5-FU could inhibit the proliferation of AGS gastric cancer cells by down-regulating the expression of p-Akt. The invasiveness of AGS cancer cell was inhibited by reduced expression of MMP-2 and E-cadherin genes, and provides a theory basis for 5-FU and apatinib combination in clinic with advanced gastric cancer patients who failed to second-line treatment but still had a good performance status.

Clinical trial identification

Legal entity responsible for the study

Bangwei Cao


National Nature Science Foundation of China


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.